Verene Stierle
Overview
Explore the profile of Verene Stierle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jolles B, Stierle V
Biochimie
. 2025 Feb;
PMID: 40015471
In humans, the release factor eRF3a exists in several forms that differ in the length of the polyglycine tract (7, 10, 11 or 12 glycines) in its N-terminal domain. For...
2.
Thoradit T, Chabi M, Aguida B, Baouz S, Stierle V, Pooam M, et al.
Commun Integr Biol
. 2024 Aug;
17(1):2384874.
PMID: 39108419
There is increasing evidence that exposure to weak electromagnetic fields (EMFs) generated by modern telecommunications or household appliances has physiological consequences, including reports of electromagnetic field hypersensitivity (EHS) leading to...
3.
Aliouat A, Hatin I, Bertin P, Francois P, Stierle V, Namy O, et al.
RNA Biol
. 2019 Oct;
17(2):227-239.
PMID: 31619139
In addition to its role in translation termination, eRF3A has been implicated in the nonsense-mediated mRNA decay (NMD) pathway through its interaction with UPF1. NMD is a RNA quality control...
4.
Jolles B, Aliouat A, Stierle V, Salhi S, Jean-Jean O
Oncotarget
. 2018 Jun;
9(40):26171-26182.
PMID: 29899850
The earliest step in the mRNA degradation process is deadenylation, a progressive shortening of the mRNA poly(A) tail by deadenylases. The question of when deadenylation takes place remains open. MYC...
5.
Tromas A, Paque S, Stierle V, Quettier A, Muller P, Lechner E, et al.
Nat Commun
. 2013 Sep;
4:2496.
PMID: 24051655
Auxin is a major plant hormone that controls most aspects of plant growth and development. Auxin is perceived by two distinct classes of receptors: transport inhibitor response 1 (TIR1, or...
6.
Zhu M, Le Moyec L, Starzec A, Stierle V, Marbeuf-Gueye C
Anticancer Res
. 2010 Oct;
30(9):3451-8.
PMID: 20944122
Unlabelled: AIM/ BACKGROUND: Various interactions between Caveolae membrane domains, multidrug resistance transporter P-glycoprotein (P-gp) and cholesterol have been suggested. We tested the assumption that anthracycline-induced P-gp and Caveolin-1 have correlated...
7.
Stierle V, Duca M, Halby L, Senamaud-Beaufort C, Capobianco M, Laigle A, et al.
Mol Pharmacol
. 2008 Feb;
73(5):1568-77.
PMID: 18299310
Reversal of the multidrug-resistant (MDR) phenotype is very important for chemotherapy success. In fact, the expression of the MDR1 gene-encoded P-glycoprotein (P-gp) actively expels antitumor agents such as daunomycin (DNM)...
8.
Marbeuf-Gueye C, Stierle V, Sudwan P, Salerno M, Garnier-Suillerot A
FEBS J
. 2007 May;
274(6):1470-80.
PMID: 17489102
The multidrug resistance-associated protein transporter ABCC1 (MRP1) is an integral plasma membrane protein involved in the multidrug resistance phenotype. It actively expels a number of cytotoxic molecules from cells. To...
9.
Stierle V, Laigle A, Jolles B
Biochem Pharmacol
. 2005 Oct;
70(10):1424-30.
PMID: 16214115
MDR1 overexpression is one form of the multidrug resistance (MDR) phenotype, which can be acquired by patients initially responsive to chemotherapy. Because of the high toxicity of the inhibitors of...
10.
Stierle V, Laigle A, Jolles B
Oligonucleotides
. 2005 Jan;
14(3):191-8.
PMID: 15625914
Small interfering RNAs (siRNAs) are powerful tools in specifically silencing gene expression. Nevertheless, their efficiency can be limited when targeting proteins with an unusually long half-life, such as P-glycoprotein (P-gp),...